The Efficacy and Safety of Rivaroxaban for Venous Thromboembolism Prophylaxis after Total Hip and Total Knee Arthroplasty
This article is part of Special Issue:
Robert D. Russell,
William R. Hotchkiss,
Justin R. Knight,
Michael H. Huo,
Robert D. Russell
Department of Orthopaedic Surgery, University of Texas Southwestern Medical Center, 1801 Inwood Road, Dallas, TX 75390-8883, USA utsouthwestern.edu
Search for more papers by this authorWilliam R. Hotchkiss
Department of Orthopaedic Surgery, University of Texas Southwestern Medical Center, 1801 Inwood Road, Dallas, TX 75390-8883, USA utsouthwestern.edu
Search for more papers by this authorJustin R. Knight
Department of Orthopaedic Surgery, University of Texas Southwestern Medical Center, 1801 Inwood Road, Dallas, TX 75390-8883, USA utsouthwestern.edu
Search for more papers by this authorCorresponding Author
Michael H. Huo
Department of Orthopaedic Surgery, University of Texas Southwestern Medical Center, 1801 Inwood Road, Dallas, TX 75390-8883, USA utsouthwestern.edu
Search for more papers by this authorRobert D. Russell,
William R. Hotchkiss,
Justin R. Knight,
Michael H. Huo,
Robert D. Russell
Department of Orthopaedic Surgery, University of Texas Southwestern Medical Center, 1801 Inwood Road, Dallas, TX 75390-8883, USA utsouthwestern.edu
Search for more papers by this authorWilliam R. Hotchkiss
Department of Orthopaedic Surgery, University of Texas Southwestern Medical Center, 1801 Inwood Road, Dallas, TX 75390-8883, USA utsouthwestern.edu
Search for more papers by this authorJustin R. Knight
Department of Orthopaedic Surgery, University of Texas Southwestern Medical Center, 1801 Inwood Road, Dallas, TX 75390-8883, USA utsouthwestern.edu
Search for more papers by this authorCorresponding Author
Michael H. Huo
Department of Orthopaedic Surgery, University of Texas Southwestern Medical Center, 1801 Inwood Road, Dallas, TX 75390-8883, USA utsouthwestern.edu
Search for more papers by this authorAcademic Editor: C. Arnold Spek
Abstract
Venous thromboembolism (VTE) is a common complication after total hip and total knee arthroplasty. Currently used methods of VTE prophylaxis after these procedures have important limitations, including parenteral administration, and unpredictable plasma levels requiring frequent monitoring and dose adjustment leading to decreased patient compliance with recommended guidelines. New oral anticoagulants have been demonstrated in clinical trials to be equally efficacious to enoxaparin and allow for fixed dosing without the need for monitoring. Rivaroxaban is one of the new oral anticoagulants and is a direct factor Xa inhibitor that has demonstrated superior efficacy to that of enoxaparin. However, the data also suggest that rivaroxaban has an increased risk of bleeding compared to enoxaparin. This paper reviews the available data on the efficacy and safety of rivaroxaban for VTE prophylaxis after total hip and total knee arthroplasty.
References
- 1 Xing K. H., Morrison G., Lim W., Douketis J., Odueyungbo A., and Crowther M., Has the incidence of deep vein thrombosis in patients undergoing total hip/knee arthroplasty changed over time? A systematic review of randomized controlled trials, Thrombosis Research. (2008) 123, no. 1, 24–34, 2-s2.0-54049134398, https://doi.org/10.1016/j.thromres.2008.05.005.
- 2 Falck-Ytter Y., Francis C. W., Johanson N. A., Curley C., Dahl O. E., Schulman S., Ortel T. L., Pauker S. G., and ColwellC. W.Jr., Prevention of VTE in orthopedic surgery patients. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines, Chest. (2012) 141, no. 2 supplement, e278S–e325S, https://doi.org/10.1378/chest.11-2404.
- 3 Huo M. H., Spencer D. L., Borah B. J., Mills R. M., Fan Y., Yarlas A., and Klaskala W., Post-discharge venous thromboembolism and bleeding in a large cohort of patients undergoing total hip or total knee arthroplasty, Journal of Clinical Outcomes Management. (2012) 19, no. 8, 355–363.
- 4 Januel J.-M., Chen G., Ruffieux C., Quan H., Douketis J. D., Crowther M. A., Colin C., Ghali W. A., and Burnand B., Symptomatic in-hospital deep vein thrombosis and pulmonary embolism following hip and knee arthroplasty among patients receiving recommended prophylaxis: a systematic review, Journal of the American Medical Association. (2012) 307, no. 3, 294–303, https://doi.org/10.1001/jama.2011.2029.
- 5 White R. H., Zhou H., and Romano P. S., Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures, Thrombosis and Haemostasis. (2003) 90, no. 3, 446–455, 2-s2.0-0141651863.
- 6 Khatod M., Inacio M. C., Bini S. A., and Paxton E. W., Prophylaxis against pulmonary embolism in patients undergoing total hip arthroplasty, Journal of Bone and Joint Surgery. (2011) 93, no. 19, 1767–1772, 2-s2.0-79957836157.
- 7 Jameson S. S., Charman S. C., Gregg P. J., Reed M. R., and van der Meulen J. H., The effect of aspirin and low-molecular-weight heparin on venous thromboembolism after hip replacement: a non-randomised comparison from information in the National Joint Registry, Journal of Bone and Joint Surgery. (2011) 93 B, no. 11, 1465–1470, https://doi.org/10.1302/0301-620X.93B11.27622.
- 8 Bjørnarå B. T., Gudmundsen T. E., and Dahl O. E., Frequency and timing of clinical venous thromboembolism after major joint surgery, Journal of Bone and Joint Surgery. (2006) 88, no. 3, 386–391.
- 9 Friedman R. J., Gallus A. S., Cushner F. D., FitzGerald G., and AndersonF. A.Jr., Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty, Current Medical Research and Opinion. (2008) 24, no. 1, 87–97, 2-s2.0-38549176207, https://doi.org/10.1185/030079907X242746.
- 10 Schuringa P. and Yen D., Home prophylactic warfarin anticoagulation program after hip and knee arthroplasty, Canadian Journal of Surgery. (1999) 42, no. 5, 360–362, 2-s2.0-0032834640.
- 11 Warwick D., Friedman R. J., Agnelli G., Gil-Garay E., Johnson K., FitzGerald G., and Turibio F. M., Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry, Journal of Bone and Joint Surgery B. (2007) 89, no. 6, 799–807, 2-s2.0-34547536841, https://doi.org/10.1302/0301-620X.89B6.18844.
- 12 Lassen M. R., Raskob G. E., Gallus A., Pineo G., Chen D., and Portman R. J., Apixaban or enoxaparin for thromboprophylaxis after knee replacement, The New England Journal of Medicine. (2009) 361, no. 6, 594–604, Erratum in: The New England Journal of Medicine, vol. 361, no. 18, p.1814, 20092-s2.0-68249158084, https://doi.org/10.1056/NEJMoa0810773.
- 13 Lassen M. R., Raskob G. E., Gallus A., Pineo G., Chen D., and Hornick P., Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial, The Lancet. (2010) 375, no. 9717, 807–815, 2-s2.0-77649113258, https://doi.org/10.1016/S0140-6736(09)62125-5.
- 14 Lassen M. R., Gallus A., Raskob G. E., Pineo G., Chen D., and Ramirez L. M., Apixaban versus enoxaparin for thromboprophylaxis after hip replacement, The New England Journal of Medicine. (2010) 363, no. 26, 2487–2498, 2-s2.0-78650587760, https://doi.org/10.1056/NEJMoa1006885.
- 15 Eriksson B. I., Dahl O. E., Rosencher N., Kurth A. A., van Dijk C. N., Frostick S. P., Kälebo P., Christiansen A. V., Hantel S., Hettiarachchi R., Schnee J., and Büller H. R., Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial, Journal of Thrombosis and Haemostasis. (2007) 5, no. 11, 2178–2185, 2-s2.0-35449007749, https://doi.org/10.1111/j.1538-7836.2007.02748.x.
- 16 Eriksson B. I., Dahl O. E., Rosencher N., Kurth A. A., van Dijk C. N., Frostick S. P., Prins M. H., Hettiarachchi R., Hantel S., Schnee J., and Büller H. R., Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial, The Lancet. (2007) 370, no. 9591, 949–956, Erratum in: The Lancet, vol. 370, no. 9604, p.2004, 20072-s2.0-34548575058, https://doi.org/10.1016/S0140-6736(07)61445-7.
- 17 RE-MOBILIZE Writing Committee, Ginsberg J. S., Davidson B. L., Comp P. C., Francis C. W., Friedman R. J., Huo M. H., Lieberman J. R., Muntz J. E., Raskob G. E., Clements M. L., Hantel S., Schnee J. M., and Caprini J. A., Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery, Journal of Arthroplasty. (2009) 24, no. 1, 1–9, https://doi.org/10.1016/j.arth.2008.01.132.
- 18 Eriksson B. I., Borris L. C., Friedman R. J., Haas S., Huisman M. V., Kakkar A. K., Bandel T. J., Beckmann H., Muehlhofer E., Misselwitz F., and Geerts W., Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty, The New England Journal of Medicine. (2008) 358, no. 26, 2765–2775, 2-s2.0-45949099359, https://doi.org/10.1056/NEJMoa0800374.
- 19 Kakkar A. K., Brenner B., Dahl O. E., Eriksson B. I., Mouret P., Muntz J., Soglian A. G., Pap Á. F., Misselwitz F., and Haas S., Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial, The Lancet. (2008) 372, no. 9632, 31–39, 2-s2.0-46049106502, https://doi.org/10.1016/S0140-6736(08)60880-6.
- 20 Lassen M. R., Ageno W., Borris L. C., Lieberman J. R., Rosencher N., Bandel T. J., Misselwitz F., and Turpie A. G. G., Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty, The New England Journal of Medicine. (2008) 358, no. 26, 2776–2786, 2-s2.0-45949103416, https://doi.org/10.1056/NEJMoa076016.
- 21 Turpie A. G., Lassen M. R., Davidson B. L., Bauer K. A., Gent M., Kwong L. M., Cushner F. D., Lotke P. A., Berkowitz S. D., Bandel T. J., Benson A., Misselwitz F., and Fisher W. D., Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial, The Lancet. (2009) 373, no. 9676, 1673–1680, 2-s2.0-65549169515, https://doi.org/10.1016/S0140-6736(09)60734-0.
- 22 Huisman M. V., Quinlan D. J., Dahl O. E., and Schulman S., Enoxaparin versus Dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: results of separate pooled analyses of phase III multicenter randomized trials, Circulation. (2010) 3, no. 6, 652–660, 2-s2.0-78650242199, https://doi.org/10.1161/CIRCOUTCOMES.110.957712.
- 23 Trkulja V. and Kolundžic R., Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on metaanalysis of pivotal clinical trials, Croatian Medical Journal. (2010) 51, no. 2, 113–123, 2-s2.0-77953735839, https://doi.org/10.3325/cmj.2010.51.113.
- 24 Xarelto Prescribing Information, 2012, http://www.xarelto-us.com/.
- 25 Eriksson B. I., Quinlan D. J., and Weitz J. I., Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development, Clinical Pharmacokinetics. (2009) 48, no. 1, 1–22, 2-s2.0-57449094606, https://doi.org/10.2165/0003088-200948010-00001.
- 26 Kubitza D., Becka M., Mueck W., Halabi A., Maatouk H., Klause N., Lufft V., Wand D. D., Philipp T., and Bruck H., Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor, British Journal of Clinical Pharmacology. (2010) 70, no. 5, 703–712, 2-s2.0-78649289929, https://doi.org/10.1111/j.1365-2125.2010.03753.x.
- 27 Kubitza D., Becka M., Zuehlsdorf M., and Mueck W., Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects, Journal of Clinical Pharmacology. (2008) 47, no. 2, 218–226, Erratum in:Journal of Clinical Pharmacology, vol. 48, no. 11, p.1366–1367, 20082-s2.0-54049092900.
- 28 Friedman R. J., Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials, Orthopedics. (2011) 34, no. 10, 795–804, https://doi.org/10.3928/01477447-20110826-24.
- 29 Turpie A. G., Lassen M. R., Kakkar A. K., Eriksson B. I., Berkowitz S. D., Misselwitz F., Bandel T. J., Homering M., Westermeier T., and Gent M., Pooled analysis of four studies of rivaroxaban: effect on symptomatic events and bleeding and the influence of clinically relevant patient subgroups, Chest. (2009) 136, no. meeting abstracts.
- 30 Turpie A. G., Lassen M. R., Eriksson B. I., Gent M., Berkowitz S. D., Misselwitz F., Bandel T. J., Homering M., Westermeier T., and Kakkar A. K., Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty: pooled analysis of four studies, Thrombosis and Haemostasis. (2011) 105, no. 3, 444–453, https://doi.org/10.1160/TH10-09-0601.
- 31 Espada N. G., Merino R. G., and González T. C., Dabigatran, Rivaroxaban and Apixaban versus Enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials, Thrombosis Research. (2012) 130, no. 2, 183–191, https://doi.org/10.1016/j.thromres.2012.02.011.
- 32 Jensen C. D., Steval A., Partington P. F., Reed M. R., and Muller S. D., Return to theatre following total hip and knee replacement, before and after the introduction of rivaroxaban: a retrospective cohort study, Journal of Bone and Joint Surgery B. (2011) 93, no. 1, 91–95, 2-s2.0-78651252397, https://doi.org/10.1302/0301-620X.93B1.24987.
- 33 Lützner J., Donath L., Tittl L., Knoth H., Radke O. C., Kuhlisch E., Stange T., Hartmann A., Günther K.-P., Weiss N., and Werth S., Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery: findings from the ORTHO-TEP registry, Thrombosis and Haemostasis. (2013) 109, no. 1, 154–163, https://doi.org/10.1160/TH12-07-0510.
